Clincosm LogoSign in Get a demo

Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM)

Sponsor
Xuzhou Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05509530
Collaborator
(none)
30
Enrollment
1
Location
1
Arm
36
Anticipated Duration (Months)
0.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is an open label, single-arm, Phase 2 study to evaluate the efficacy and safety of Anti-BCMA/GPRC5D CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture Anti-BCMA/GPRC5D chimeric antigen receptor (CAR) modified T cells. Prior to Anti-BCMA/GPRC5D infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.

Condition or Disease Intervention/Treatment Phase
  • Other: anti-BCMA/GPRC5D CAR-T CELL
 Phase 2

Detailed Description

This open label, single-arm, Phase 2 study aims to evaluate the efficacy and safety of Anti-BCMA/GPRC5D CAR-T in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture Anti-BCMA/GPRC5D chimeric antigen receptor (CAR) modified T cells. Prior to Anti-BCMA/GPRC5D infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide. After infusion, the investigators will observe the characteristics of dose limited toxicity (DLT), and determine the maximum tolerable agent MTD and rp2d were confirmed. To provide basis for the dosage and treatment plan of cell products in follow-up clinical trials.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Efficacy and Safety Study of Anti-BCMA/GPRC5D CAR-T Cells in Subjects With Relapsed and Refractory Multiple Myeloma
Actual Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
May 1, 2025
Anticipated Study Completion Date :
May 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: anti BCMA/GPRC5D CAR-T

Enrolled patients will receive prespecified dose of autologous anti BCMA/GPRC5D CAR-T cells.

Other: anti-BCMA/GPRC5D CAR-T CELL
anti-BCMA/GPRC5D autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy

Outcome Measures

Primary Outcome Measures

  1. Number of participants with Adverse Events, with abnormal vital signs, abnormal physical examination findings, abnormal laboratory test results, abnormal ECGs and abnormal echocardiograms. [12 months]

Secondary Outcome Measures

  1. overall response rate (ORR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM [24 months]

    Percentage of subjects who achieved a CR, VGR, PR according to IMWG Uniform Response Criteria for Multiple Myeloma (MM)

  2. complete response (CR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM [24 months]

    Percentage of subjects who achieved a CR according to IMWG Uniform Response Criteria for Multiple Myeloma (MM)

  3. very good partial response (VGPR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM [24 months]

    Percentage of subjects who achieved a VGPR according to IMWG Uniform Response Criteria for Multiple Myeloma (MM)

  4. partial response (PR) according to the International Myeloma Working Group (IMWG) Uniform Response Criteria for MM [24 months]

    Percentage of subjects who achieved a PR according to IMWG Uniform Response Criteria for Multiple Myeloma (MM)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  1. Age and gender: 18 years old <= age <= 70 years old, gender unlimited, signing informed consent voluntarily;

  2. According to the classification definition of IMWG standard, the diagnosis of plasmacytoma is multiple myeloma, plasmacytic leukemia, poems syndrome, monoclonal IMMUNOGLOBULINEMIA, primary macroglobulinemia or primary amyloidosis which are invalid or relapsed after at least three-line treatment (including chemotherapy based on bortezomib and / or lenalidomide);

  3. BCMA and GPRC5D were positive on the surface of plasma membrane;

  4. The patients could not receive the treatment of HSCT, or the relapse after HSCT was judged to need treatment by researchers;

  5. ECOG score is 0 or 1;

  6. Expected survival time >= 12 weeks;

  7. The subjects must have proper organ function and meet all the following laboratory test results before entering the group

  8. Blood routine test: neutrophil >= 1.0 x 109 / L; hemoglobin >= 70 g / L; platelet >= 50 x 109 / L;

  9. Liver function: ALT and AST <= 2.5 x ULN; total bilirubin <= 1.5 x ULN;

  10. Renal function: serum creatinine <= 2.5 x ULN; or creatinine clearance calculated according to Cockcroft Gault formula Rate CrCl >= 60 ml / min.

  11. Electrolyte: blood potassium >= 3.0 mmol / L; blood calcium >= 2.0 mmol / L; blood magnesium >= 0.5 mmol / L;

  12. Coagulation function: fibrinogen >= 1.0g/l; activated partial thromboplastin time (APTT) <= Keywords ULN + 10s; prothrombin time (PT) < ULN + 3S;

  13. The subjects should be willing to provide effective diagnosis evidence or bone marrow examination before treatment, and bone marrow or effective examination after treatment;

  14. Women of childbearing age and fertile male subjects must take one of the following effective contraceptive measures from signing informed consent until one year after anti-BCMA/GPRC5D CAR-T cell transfusion: abstinence, double barrier contraceptive method, IUD, hormone contraceptive;

  15. Male subjects were forbidden to donate sperm from signing the informed consent until one year after anti-BCMA/GPRC5D CAR-T cell transfusion;

  16. Sign informed consent

  17. The subject must have informed consent to the test before the test, and be voluntary by himself (or his legal representative) signed the written informed consent;

  18. The subjects or their legal representatives can communicate well with the researchers and follow the protocol to complete the test.

Exclusion Criteria:

  1. Previous treatment history

  2. Received hematopoietic stem cell transplantation within 2 months before the start of administration, or within the screening period after transplantation, immunosuppressive therapy was used because of graft-versus-host disease;

  3. Patients who had received chemotherapy, immunotherapy, radiotherapy and major surgery within 4 weeks before the start of administration;

  4. Those who received the live vaccine within 4 weeks before the start of administration and / or planned to receive the live vaccine after the trial;

  5. Those who have received clinical trial drug treatment or are participating in other clinical trials within 4 weeks before drug administration;

  6. History of disease and operation

  7. Patients with central nervous system invasion by plasmacytoma;

  8. Hypertension and drug treatment can not get good control (blood pressure > 140 / 90 mmHg);

  9. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) < 50%;

  10. Arrhythmia with NCI CTCAE 5.0 grade >= 2, or male QTc > 450 ms, female QTc > 470 MS (QTc was calculated by the friderica correction formula QTc = QT / rr0.33); patients with a history of tip torsion or congenital QT prolongation syndrome;

  11. Patients with any of the following diseases within 12 months before administration: myocardial infarction, severe or unstable heart, patients with colic, coronary artery bypass or peripheral artery bypass grafting, congestive heart failure, cerebrovascular events (including transient ischemic attack), etc;

  12. During the screening period, the researchers judged that there were uncontrollable and active infectious diseases;

  13. People infected with human immunodeficiency virus (HIV);

  14. HBsAg was positive and in the active phase of hepatitis B (HBV DNA quantity >= 1.00 x 10^2 copies / ml);

  15. Hepatitis C antibody (anti HCV) was positive and was in the active phase of hepatitis C (hepatitis C RNA was not in the normal mode)Perimetric value);

  16. The researchers judged patients with severe electrolyte disorder;

  17. Patients with a clear tendency of gastrointestinal bleeding, including the following: local active ulcer focus, and stool occult blood (>= + +); patients with a history of black stool and hematemesis within 2 months; researchers believe that digestion may occur Patients with massive bleeding of the Tao;

  18. Patients with a history of solid organ transplantation;

  19. The investigator or sponsor thinks that he / she has other acute, serious or chronic medical or psychological diseases and is not suitable for participation Add clinical trial;

  20. Pregnant and nursing women

  21. Prohibited treatment and / or medication

  22. At the same time, other anti-tumor drugs, including traditional Chinese medicine, were used;

  23. At the same time, take drugs that can prolong QT interval (including class IA and III antiarrhythmic drugs);

  24. Those who need to receive oxygen every day;

  25. Long term use of corticosteroids (except for local inhalation);

  26. others

  27. Those who have a history of psychoactive drug abuse and are unable to give up or have mental disorders;

  28. Habitually drink grapefruit juice or excessive tea, coffee and / or caffeinated beverages during the trial Unable to give up;

  29. According to the judgment of the researchers, there are serious concomitant diseases endangering the safety of patients or affecting the completion of the trialillnes.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kailin Xu Xuzhou Jiangsu China 221000

Sponsors and Collaborators

  • Xuzhou Medical University

Investigators

  • Principal Investigator: Kailin Xu, M.D., Ph.D., Xuzhou Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kai Lin Xu，MD, Principal Investigator, Xuzhou Medical University
ClinicalTrials.gov Identifier:
NCT05509530
Other Study ID Numbers:
  • XYFY2022-KL118-01
First Posted:
Aug 22, 2022
Last Update Posted:
Aug 22, 2022
Last Verified:
Aug 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Kai Lin Xu，MD, Principal Investigator, Xuzhou Medical University
Multiple Myeloma
BCMA
GPRC5D
Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell

Study Results

No Results Posted as of Aug 22, 2022